{"id":24704,"date":"2023-11-07T09:02:00","date_gmt":"2023-11-07T09:02:00","guid":{"rendered":"https:\/\/ameripharmaspecialty.com\/?p=24704"},"modified":"2026-03-20T14:39:21","modified_gmt":"2026-03-20T21:39:21","slug":"perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/","title":{"rendered":"Perjeta (Pertuzumab): Un medicamento prometedor para el c\u00e1ncer de mama HER2 positivo"},"content":{"rendered":"<p>HER2 (receptor 2 del factor de crecimiento epid\u00e9rmico humano) es una prote\u00edna que se encuentra en la superficie de algunas c\u00e9lulas (por ejemplo, las c\u00e9lulas mamarias) y que desempe\u00f1a un papel en el crecimiento y la divisi\u00f3n celular.&nbsp;<\/p>\n\n\n\n<p>En ocasiones, las c\u00e9lulas de c\u00e1ncer de mama pueden tener demasiadas copias del gen HER2, lo que provoca un exceso de prote\u00edna HER2 en la superficie celular. Esta afecci\u00f3n se conoce como c\u00e1ncer de mama HER2 positivo. Acerca de&nbsp;<a href=\"https:\/\/www.cancer.org\/cancer\/breast-cancer\/understanding-a-breast-cancer-diagnosis\/breast-cancer-her2-status.html\">15% a 20%<\/a>&nbsp;de los tumores de mama tienen niveles m\u00e1s elevados de HER2.&nbsp;<\/p>\n\n\n\n<p>Las opciones de tratamiento para el c\u00e1ncer HER2 positivo pueden incluir cirug\u00eda, radioterapia, quimioterapia, hormonoterapia y terapias dirigidas como Perjeta (pertuzumab). Este art\u00edculo destaca la eficacia de Perjeta para el tratamiento del c\u00e1ncer HER2 positivo y explica c\u00f3mo funciona el medicamento y c\u00f3mo se utiliza en el tratamiento.<\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenido\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Palanca<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#What_Is_Perjeta\" >\u00bfQu\u00e9 es Perjeta?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#What_Is_Perjeta_Used_For\" >\u00bfPara qu\u00e9 se utiliza Perjeta?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#How_Does_Perjeta_Work\" >\u00bfC\u00f3mo funciona Perjeta?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#Dose\" >Dosis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#Side_Effects\" >Efectos secundarios<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#Precautions\" >Precauciones<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#Cost\" >Costo<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Is_Perjeta\"><\/span>\u00bfQu\u00e9 es Perjeta?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Perjeta es un anticuerpo monoclonal que se utiliza para tratar ciertos tipos de c\u00e1ncer de mama. Pertenece a una clase de medicamentos conocidos como inhibidores de HER2, que atacan la prote\u00edna HER2 presente en la superficie de algunas c\u00e9lulas de c\u00e1ncer de mama.<\/p>\n\n\n\n<p>La droga era&nbsp;<a href=\"https:\/\/www.fiercepharma.com\/pharma\/fda-approves-perjeta-for-neoadjuvant-breast-cancer-treatment#:~:text=Perjeta%20is%20the%20first%20FDA,)%20HER2%2Dpositive%20breast%20cancer.\">Aprobado por la FDA de EE. UU.<\/a>&nbsp;En 2012, se aprob\u00f3 su uso en combinaci\u00f3n con otros medicamentos para tratar el c\u00e1ncer de mama HER2 positivo que se ha propagado a otras partes del cuerpo (c\u00e1ncer de mama metast\u00e1sico) o que est\u00e1 localmente avanzado y no puede extirparse quir\u00fargicamente. La FDA tambi\u00e9n lo aprob\u00f3 para el tratamiento neoadyuvante (preoperatorio) del c\u00e1ncer de mama HER2 positivo con otros medicamentos.<\/p>\n\n\n\n<p>La aprobaci\u00f3n de Perjeta se bas\u00f3 en&nbsp;<a href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02132949\">ensayos cl\u00ednicos<\/a>&nbsp;que demostr\u00f3 ser eficaz para retrasar la progresi\u00f3n de la enfermedad y mejorar la supervivencia general en pacientes con c\u00e1ncer de mama HER2 positivo.&nbsp;<\/p>\n\n\n\n<p>En un estudio, los pacientes que recibieron Perjeta en combinaci\u00f3n con quimioterapia y otro inhibidor de HER2, Herceptin (trastuzumab), sobrevivieron m\u00e1s tiempo en comparaci\u00f3n con aquellos que recibieron solo quimioterapia y Herceptin.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Is_Perjeta_Used_For\"><\/span>\u00bfPara qu\u00e9 se utiliza Perjeta?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Perjeta se usa con otros medicamentos, como\u00a0<a href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/trastuzumab-herceptin\/\">Herceptin<\/a>\u00a0(trastuzumab) y Taxotere (<a href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/docetaxel-taxotere\/\">docetaxel<\/a>), para tratar:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>C\u00e1ncer de mama metast\u00e1sico<\/strong>:C\u00e1ncer de mama HER2 positivo que se ha propagado a otras partes del cuerpo.&nbsp;<\/li>\n\n\n\n<li><strong>C\u00e1ncer de mama en etapa temprana:<\/strong>&nbsp;El c\u00e1ncer debe estar en los ganglios linf\u00e1ticos o medir m\u00e1s de 2 cm.<\/li>\n\n\n\n<li><strong>C\u00e1ncer de mama localmente avanzado<\/strong>C\u00e1ncer de mama HER2 positivo que no se puede extirpar quir\u00fargicamente.<\/li>\n\n\n\n<li><strong>Tratamiento neoadyuvante<\/strong>C\u00e1ncer de mama HER2 positivo antes de la cirug\u00eda para reducir el tama\u00f1o del tumor y aumentar las posibilidades de una extirpaci\u00f3n quir\u00fargica exitosa.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_Does_Perjeta_Work\"><\/span>\u00bfC\u00f3mo funciona Perjeta?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Perjeta ataca y bloquea la prote\u00edna HER2 en la superficie de las c\u00e9lulas cancerosas, lo que ayuda a retardar el crecimiento y la propagaci\u00f3n de las c\u00e9lulas cancerosas.<\/p>\n\n\n\n<p>HER2 normalmente interact\u00faa con otras prote\u00ednas, como HER3, y activa v\u00edas de se\u00f1alizaci\u00f3n dentro de la c\u00e9lula cancerosa que aumentan el crecimiento y la supervivencia celular. Esta activaci\u00f3n puede provocar el crecimiento y la propagaci\u00f3n descontrolados de las c\u00e9lulas cancerosas.<\/p>\n\n\n\n<p>Perjeta se une a una parte espec\u00edfica de la prote\u00edna HER2, denominada dominio extracelular, que se encuentra en la superficie externa de las c\u00e9lulas cancerosas. Al unirse a esta regi\u00f3n, Perjeta impide que HER2 interact\u00fae con otras prote\u00ednas y v\u00edas de se\u00f1alizaci\u00f3n que promueven el crecimiento y la divisi\u00f3n de las c\u00e9lulas cancerosas.<\/p>\n\n\n\n<p>Perjeta tambi\u00e9n puede inducir citotoxicidad celular dependiente de anticuerpos (ADCC), que es un proceso mediante el cual se reclutan c\u00e9lulas inmunes (c\u00e9lulas asesinas naturales) para atacar y matar c\u00e9lulas cancerosas que han sido marcadas con Perjeta.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dose\"><\/span>Dosis<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La dosis depende de varios factores, como su peso corporal, sus antecedentes m\u00e9dicos y el estadio y tipo de c\u00e1ncer de mama que se est\u00e9 tratando. Antes de comenzar el tratamiento con Perjeta, un profesional de la salud le realizar\u00e1 una prueba para determinar si tiene c\u00e1ncer HER2 positivo.&nbsp;<\/p>\n\n\n\n<p>En general, la dosis t\u00edpica es de 840 mg administrados como infusi\u00f3n intravenosa (IV) durante 60 minutos, luego 420 mg administrados como infusi\u00f3n intravenosa durante 30 a 60 minutos cada 3 semanas. Perjeta se administra en combinaci\u00f3n con Herceptin (trastuzumab) y otra quimioterapia.<\/p>\n\n\n\n<p>El Perjeta se administra mediante infusi\u00f3n intravenosa por un profesional de la salud en un hospital o cl\u00ednica. El tiempo y la frecuencia de la infusi\u00f3n pueden variar seg\u00fan el r\u00e9gimen de tratamiento espec\u00edfico y la respuesta del paciente. Para garantizar un uso seguro y eficaz, es fundamental que los pacientes sigan las instrucciones de dosificaci\u00f3n y administraci\u00f3n proporcionadas por su profesional de la salud.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Side_Effects\"><\/span>Efectos secundarios<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Como cualquier medicamento, Perjeta (pertuzumab) puede causar efectos secundarios, aunque no todos los pacientes los experimentan. Algunos efectos secundarios comunes incluyen:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Diarrea<\/li>\n\n\n\n<li>N\u00e1useas y v\u00f3mitos<\/li>\n\n\n\n<li>Fatiga<\/li>\n\n\n\n<li>P\u00e9rdida de cabello<\/li>\n\n\n\n<li>Sarpullido o irritaci\u00f3n de la piel<\/li>\n\n\n\n<li>Dolor abdominal<\/li>\n\n\n\n<li>Dolor muscular<\/li>\n\n\n\n<li>Dolor de cabeza<\/li>\n\n\n\n<li>Disminuci\u00f3n del apetito<\/li>\n\n\n\n<li>Anemia<\/li>\n<\/ul>\n\n\n\n<p>Los efectos secundarios m\u00e1s graves pueden incluir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Insuficiencia cardiaca<\/li>\n\n\n\n<li>Reacciones a la infusi\u00f3n<\/li>\n\n\n\n<li>Infecciones<\/li>\n\n\n\n<li>Hipersensibilidad y reacciones al\u00e9rgicas<\/li>\n<\/ul>\n\n\n\n<p>Es importante notificar al profesional de la salud inmediatamente si se presenta alguno de estos efectos secundarios. El profesional de la salud podr\u00eda ajustar la dosis o brindar atenci\u00f3n de apoyo para controlar los efectos secundarios. En algunos casos, podr\u00eda ser necesario suspender o retrasar el tratamiento con Perjeta para prevenir efectos secundarios adicionales.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Precautions\"><\/span>Precauciones<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Personas con antecedentes de enfermedad card\u00edaca o que hayan recibido previamente tratamiento con&nbsp;<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538187\/#:~:text=Anthracyclines%20are%20drugs%20extracted%20from,effective%20anticancer%20drugs%20to%20date.\">antraciclinas<\/a>&nbsp;Debe ser monitoreado de cerca durante el tratamiento.<\/li>\n\n\n\n<li>Las mujeres embarazadas o en per\u00edodo de lactancia no deben recibir Perjeta debido al riesgo de da\u00f1o a los beb\u00e9s.<\/li>\n\n\n\n<li>Las personas que hayan tenido una reacci\u00f3n al\u00e9rgica al Perjeta o a cualquiera de sus componentes no deben recibir este medicamento.<\/li>\n\n\n\n<li>Las personas con enfermedad hep\u00e1tica o renal a\u00fan podr\u00edan recibir Perjeta, pero podr\u00edan requerir control adicional y ajuste de su dosis.<\/li>\n\n\n\n<li>Los pacientes que reciben Perjeta deben evitar recibir vacunas vivas porque no se sabe qu\u00e9 tan bien reaccionar\u00e1 su cuerpo a las vacunas.<\/li>\n\n\n\n<li>Los pacientes deben informar a su proveedor de atenci\u00f3n m\u00e9dica sobre todos los medicamentos, incluidos los recetados, los de venta libre y los suplementos a base de hierbas, que est\u00e9n tomando para asegurarse de que nada reaccione con Perjeta.<\/li>\n\n\n\n<li>Los pacientes que tengan programada una cirug\u00eda deben informar a su proveedor de atenci\u00f3n m\u00e9dica que est\u00e1n tomando Perjeta.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Cost\"><\/span>Costo<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La soluci\u00f3n intravenosa (IV) de Perjeta (420 mg por 14 ml) cuesta aproximadamente $5,534. Este costo podr\u00eda superar los $99,000 durante un a\u00f1o de tratamiento. Si no puede costear el medicamento, podr\u00eda obtener descuentos o inscribirse en programas de asistencia financiera para ayudar a compensar el costo.<\/p>","protected":false},"excerpt":{"rendered":"<p>HER2 (receptor 2 del factor de crecimiento epid\u00e9rmico humano) es una prote\u00edna que se encuentra en la superficie de algunas c\u00e9lulas (por ejemplo, las c\u00e9lulas mamarias) y que desempe\u00f1a un papel en el crecimiento y la divisi\u00f3n celular.<br \/>\nA veces, las c\u00e9lulas del c\u00e1ncer de mama pueden tener demasiadas copias del gen HER2, lo que genera demasiada prote\u00edna HER2 en la superficie de las c\u00e9lulas.<\/p>","protected":false},"author":26,"featured_media":24705,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":true,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[64],"tags":[],"class_list":["post-24704","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-discontinued"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Perjeta (Pertuzumab): A Promising Medication for HER2-Positive Breast Cancer<\/title>\n<meta name=\"description\" content=\"Find out how Perjeta treats HER2-positive breast cancer. Topics include how the drug works, dosage, side effects, precautions, and cost.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Perjeta (Pertuzumab): A Promising Medication for HER2-Positive Breast Cancer\" \/>\n<meta property=\"og:description\" content=\"Find out how Perjeta treats HER2-positive breast cancer. Topics include how the drug works, dosage, side effects, precautions, and cost.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-07T09:02:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-20T21:39:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Robert Hakim, PharmD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Robert Hakim, PharmD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/\"},\"author\":{\"name\":\"Dr. Robert Hakim, PharmD\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#\\\/schema\\\/person\\\/234280933b6e0dcaf47c0c1f40a59759\"},\"headline\":\"Perjeta (Pertuzumab): A Promising Medication for HER2-Positive Breast Cancer\",\"datePublished\":\"2023-11-07T09:02:00+00:00\",\"dateModified\":\"2026-03-20T21:39:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/\"},\"wordCount\":979,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg\",\"articleSection\":[\"Discontinued\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/\",\"name\":\"Perjeta (Pertuzumab): A Promising Medication for HER2-Positive Breast Cancer\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg\",\"datePublished\":\"2023-11-07T09:02:00+00:00\",\"dateModified\":\"2026-03-20T21:39:21+00:00\",\"description\":\"Find out how Perjeta treats HER2-positive breast cancer. Topics include how the drug works, dosage, side effects, precautions, and cost.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg\",\"width\":1280,\"height\":853,\"caption\":\"Medication for HER2-positive breast cancer treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/discontinued\\\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Perjeta (Pertuzumab): A Promising Medication for HER2-Positive Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/#\\\/schema\\\/person\\\/234280933b6e0dcaf47c0c1f40a59759\",\"name\":\"Dr. Robert Hakim, PharmD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g\",\"caption\":\"Dr. Robert Hakim, PharmD\"},\"description\":\"Dr. Robert Chad Hakim, PharmD, was born and raised in Northridge, CA. He received his pharmacy degree from the University of Wisconsin-Madison School of Pharmacy. The most rewarding part of his job is taking initiative to advance clinical programs that maximize impact on patient care. He has a board certification in critical care (BCCCP), and his areas of expertise are critical care, drug information, general medicine, and cardiology. In his free time, he enjoys traveling.\u00a0\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/author\\\/robert-hakim\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Perjeta (Pertuzumab): Un medicamento prometedor para el c\u00e1ncer de mama HER2 positivo","description":"Descubra c\u00f3mo Perjeta trata el c\u00e1ncer de mama HER2 positivo. Los temas incluyen c\u00f3mo funciona el f\u00e1rmaco, la dosis, los efectos secundarios, las precauciones y el costo.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/","og_locale":"es_MX","og_type":"article","og_title":"Perjeta (Pertuzumab): A Promising Medication for HER2-Positive Breast Cancer","og_description":"Find out how Perjeta treats HER2-positive breast cancer. Topics include how the drug works, dosage, side effects, precautions, and cost.","og_url":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2023-11-07T09:02:00+00:00","article_modified_time":"2026-03-20T21:39:21+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg","type":"image\/jpeg"}],"author":"Dr. Robert Hakim, PharmD","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Robert Hakim, PharmD","Est. reading time":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/zh\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/"},"author":{"name":"Dr. Robert Hakim, PharmD","@id":"https:\/\/ameripharmaspecialty.com\/vi\/#\/schema\/person\/234280933b6e0dcaf47c0c1f40a59759"},"headline":"Perjeta (Pertuzumab): A Promising Medication for HER2-Positive Breast Cancer","datePublished":"2023-11-07T09:02:00+00:00","dateModified":"2026-03-20T21:39:21+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/"},"wordCount":979,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/vi\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg","articleSection":["Discontinued"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/zh\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/","url":"https:\/\/ameripharmaspecialty.com\/zh\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/","name":"Perjeta (Pertuzumab): Un medicamento prometedor para el c\u00e1ncer de mama HER2 positivo","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/vi\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg","datePublished":"2023-11-07T09:02:00+00:00","dateModified":"2026-03-20T21:39:21+00:00","description":"Descubra c\u00f3mo Perjeta trata el c\u00e1ncer de mama HER2 positivo. Los temas incluyen c\u00f3mo funciona el f\u00e1rmaco, la dosis, los efectos secundarios, las precauciones y el costo.","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/zh\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/zh\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg","width":1280,"height":853,"caption":"Medication for HER2-positive breast cancer treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/zh\/discontinued\/perjeta-pertuzumab-a-promising-medication-for-her2-positive-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/vi\/"},{"@type":"ListItem","position":2,"name":"Perjeta (Pertuzumab): A Promising Medication for HER2-Positive Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/vi\/#website","url":"https:\/\/ameripharmaspecialty.com\/vi\/","name":"Cuidado especializado AmeriPharma\u00ae","description":"Atenci\u00f3n especializada por AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/vi\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/vi\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/vi\/#organization","name":"Atenci\u00f3n especializada de Ameripharma","url":"https:\/\/ameripharmaspecialty.com\/vi\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/vi\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/vi\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/vi\/#\/schema\/person\/234280933b6e0dcaf47c0c1f40a59759","name":"Dr. Robert Hakim, Doctor en Farmacia","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g","caption":"Dr. Robert Hakim, PharmD"},"description":"El Dr. Robert Chad Hakim, PharmD, naci\u00f3 y creci\u00f3 en Northridge, California. Obtuvo su t\u00edtulo en farmacia en la Facultad de Farmacia de la Universidad de Wisconsin-Madison. Lo m\u00e1s gratificante de su trabajo es tomar la iniciativa para impulsar programas cl\u00ednicos que maximicen el impacto en la atenci\u00f3n al paciente. Cuenta con una certificaci\u00f3n del consejo en cuidados cr\u00edticos (BCCCP) y sus \u00e1reas de especializaci\u00f3n son cuidados cr\u00edticos, informaci\u00f3n sobre medicamentos, medicina general y cardiolog\u00eda. En su tiempo libre, disfruta viajando.\u00a0","url":"https:\/\/ameripharmaspecialty.com\/es\/author\/robert-hakim\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-300x200.jpg",300,200,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-768x512.jpg",768,512,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",1280,853,false]},"uagb_author_info":{"display_name":"Dr. Robert Hakim, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/robert-hakim\/"},"uagb_comment_info":0,"uagb_excerpt":"HER2 (human epidermal growth factor receptor 2) is a protein found on the surface of some cells (e.g., breast cells) that plays a role in cell growth and division. Sometimes, breast cancer cells can have too many copies of the HER2 gene, leading to too much HER2 protein on the surface of the cells.","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",1280,853,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",1280,853,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-300x200.jpg",300,200,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/02\/Perjeta-Pertuzumab-A-Promising-Medication-for-HER2-Positive-Breast-Cancer.jpg",1280,853,false]},"rttpg_author":{"display_name":"Dr. Robert Hakim, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/robert-hakim\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/discontinued\/\" rel=\"category tag\">Discontinued<\/a>","rttpg_excerpt":"HER2 (human epidermal growth factor receptor 2) is a protein found on the surface of some cells (e.g., breast cells) that plays a role in cell growth and division. Sometimes, breast cancer cells can have too many copies of the HER2 gene, leading to too much HER2 protein on the surface of the cells.","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/24704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/comments?post=24704"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/24704\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media\/24705"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media?parent=24704"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/categories?post=24704"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/tags?post=24704"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}